Core Viewpoint - AbbVie has submitted a supplemental New Drug Application (sNDA) to the FDA for a fixed-duration, all-oral combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL), potentially offering a new treatment option with time-limited therapy [1][2]. Group 1: Clinical Trial Results - The submission is based on positive results from the Phase 3 AMPLIFY trial, which demonstrated that the combination of VENCLEXTA and acalabrutinib improved progression-free survival (PFS) compared to standard chemoimmunotherapy in previously untreated CLL patients [2][3]. - The AMPLIFY trial showed a 35% reduction in the risk of disease progression or death with the fixed-duration combination regimen compared to chemoimmunotherapy (HR 0.65; 95% CI: 0.49-0.87; p=0.004) [3]. Group 2: Safety Profile - The safety profile of the VENCLEXTA and acalabrutinib combination is consistent with the known safety profiles of each therapy alone, with common adverse events including neutropenia, hemorrhage, and COVID-19 [3]. - Neutropenia was the most frequent Grade 3 or higher adverse event, occurring in 26.8% of patients, while low rates of tumor lysis syndrome were observed at 0.3% for the combination compared to 3.1% for chemoimmunotherapy [3]. Group 3: Product Information - VENCLEXTA (venetoclax) is a first-in-class medication that selectively inhibits the B-cell lymphoma-2 (BCL-2) protein, which is involved in preventing cancer cell apoptosis [4]. - VENCLEXTA is developed by AbbVie and Roche, and is approved in over 80 countries, including the U.S., with ongoing research into its use across various blood cancers [5]. Group 4: Company Commitment - AbbVie is dedicated to transforming cancer care through a dynamic pipeline of investigational therapies targeting various cancer types, focusing on creating targeted medicines to impede cancer cell reproduction or enable their elimination [23][25].